Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul:128:104429.
doi: 10.1016/j.jcv.2020.104429. Epub 2020 May 15.

Evaluation of the COVID19 ID NOW EUA assay

Stephanie L Mitchell  1 , Kirsten St George  2
Affiliations

Evaluation of the COVID19 ID NOW EUA assay

Stephanie L Mitchell et al. J Clin Virol. 2020 Jul.

Abstract

Background: The SARS-CoV-2 pandemic caused a major surge in needed diagnostic capacity. In response, many EUA assays have become available for clinical laboratories, and more recently, the point of care device, Abbott ID NOW.

Objectives: To determine the analytical performance of the ID NOW assay for detecting SARS-CoV-2.

Study design: Residual NP samples collected in viral transport media were tested by the ID NOW platform in two independent laboratories. Results were compared to either the CDC or New York EUA assays, which served as reference methods.

Results: Overall agreement of ID NOW was 78.7%. Sensitivity was 71.7% and specificity was 100%. Notably, all false-negative results correlated to those samples that were weakly positive.

Conclusions: ID NOW performs well for strong and moderately positive samples but has reduced sensitivity for weakly positive samples. This sensitivity, among other concerns, should be taken into consideration when using this test for patients with a low suspicion for COVID-19 disease.

Keywords: COVID-19; ID NOW; Point-of-Care; SARS-CoV-2.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
False-negative Results. False-negative samples are stratified by CT value by reference method. FN; false-negative.
See this image and copyright information in PMC

References

    1. ID NOW COVID-19 . Abbott Diagnostics Scarborough, Inc.; 2020. FDA Authorization Letter- March 27. https://www.fda.gov/medical-devices/emergency-situations-medical-devices... (Accessed 18 April 2020) Last updated: April 17, 2020.
    1. ID NOW COVID-19 . Abbott Diagnostics Scarborough, Inc.; 2020. Instructions for Use. EUA2000047. https://www.fda.gov/medical-devices/emergency-situations-medical-devices... (Accessed 18 April 18 2020) Last updated: April 17, 2020.
    1. Zhen W., Smith E., Manji R., Schron D., Berry G.J. Clinical evaluation of three sample-to-answer platforms for the detection of SARS-CoV-2. J. Clin. Microbiol. 2020 - PMC - PubMed
    1. Harrington A., Cox B., Snowdon J., Bakst J., Ley E., Grajales P., Maggiore J., Kahn S. Comparison of Abbott ID NOW and Abbott m2000 methods for the detection of SARS-Cov-2 from nasopharyngeal and nasal swabs from symptomatic patients. J. Clin. Microbiol. 2020 doi: 10.1128/JCM.00798-20. - DOI - PMC - PubMed
    1. Rhoads D.D., Cherian S.S., Roman K., Stempak L.M., Schmotzer C.L., Sadri N. Comparison of Abbott ID NOW, DiaSorin Simplexa and CDC FDA EUA methods for the detection of SARS-CoV-2 from nasopharyngeal and nasal swabs from individuals diagnosed with COVID-19. J. Clin. Microbiol. 2020 doi: 10.1128/JCM.00760-20. - DOI - PMC - PubMed

Publication types